Prometheus, Bayer Schering in Cancer PGx Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories said today that it has struck a license and development agreement with Bayer Schering Pharma for oncology diagnostics that could net Prometheus as much as $160 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.